Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Allurion Technologies, Inc. ALUR

Healthcare  —  Medical Devices
1.11 0.00 0.00% as of 25 Sep
Market cap
$16.7M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Allurion Technologies, Inc. (ALUR) Business Profile

Updated before January 2025

Company Overview

Allurion Technologies, Inc. (ALUR) is a pioneering company in the health and wellness sector, specializing in innovative weight loss solutions. Founded in 2009 by Dr. Shantanu Gaur and Samuel Levy, the company is headquartered in Natick, Massachusetts, USA. The founders envisioned a non-invasive, scalable, and effective solution to address the global obesity epidemic. Over the years, Allurion has grown into a global leader in the field of medical devices and digital health, with a presence in over 50 countries. The company is led by Dr. Shantanu Gaur, who serves as the CEO, and a team of seasoned executives with expertise in healthcare, technology, and business development.

Core Business Segments

1. Medical Devices

Allurion’s flagship product is the Allurion Balloon, a swallowable, non-invasive gastric balloon designed to aid in weight loss. Unlike traditional gastric balloons, the Allurion Balloon does not require surgery, endoscopy, or anesthesia for placement or removal. It is designed to be naturally excreted after approximately 16 weeks, making it a convenient and patient-friendly option.

2. Digital Health Solutions

Allurion offers a comprehensive digital health platform that complements its medical devices. This includes the Allurion App, a mobile application that tracks weight loss progress, provides nutritional guidance, and connects users with healthcare professionals. The app integrates seamlessly with the Allurion Connected Scale and Health Tracker, offering a holistic approach to weight management.

3. Professional Services

The company provides training and support services for healthcare providers who offer Allurion products. This includes certification programs, marketing support, and access to a global network of experts in weight management.

Business Model

Allurion operates on a B2B2C (business-to-business-to-consumer) model. The company partners with healthcare providers, clinics, and hospitals to distribute its products and services. Revenue is generated through the sale of medical devices, subscriptions to its digital health platform, and professional training services. By integrating medical devices with digital health solutions, Allurion creates a recurring revenue stream while enhancing patient outcomes.

Strategic Direction

Allurion is focused on expanding its global footprint and enhancing its product portfolio. The company aims to:

  • Expand Market Reach: Enter new geographic markets, particularly in Asia and Latin America, where obesity rates are rising.
  • Innovate Products: Develop next-generation medical devices and digital tools to improve patient outcomes.
  • Sustainability Goals: Reduce the environmental impact of its products and operations by adopting sustainable practices.
  • Collaborations: Partner with leading healthcare organizations and technology companies to drive innovation and scale.

Competitive Landscape

Allurion operates in a highly competitive market, facing competition from companies in the medical device and digital health sectors. Key competitors include:

  • Apollo Endosurgery: Known for its endoscopic weight loss solutions, including the Orbera Intragastric Balloon.
  • Reshape Lifesciences: Offers a range of weight loss devices and programs.
  • Medtronic: A global leader in medical devices, including bariatric surgery solutions.
  • Noom: A digital health company specializing in weight loss and behavioral change programs.

Despite the competition, Allurion differentiates itself through its non-invasive approach, integrated digital health platform, and strong focus on patient experience.

Risk Factors

Allurion faces several risks that could impact its business:

  • Market Dependence: Reliance on the success of the Allurion Balloon and associated services.
  • Regulatory Challenges: Compliance with medical device regulations in multiple countries.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers.
  • Economic Factors: Sensitivity to economic downturns, which could affect consumer spending on elective healthcare solutions.

Recent Developments

  • Product Innovations: In 2023, Allurion launched an updated version of its digital health platform, featuring enhanced AI-driven insights and personalized coaching.
  • Global Expansion: The company entered new markets in Southeast Asia and South America, strengthening its international presence.
  • Strategic Partnerships: Collaborated with leading healthcare providers to expand access to its weight loss solutions.
  • Sustainability Initiatives: Introduced eco-friendly packaging for its products and committed to reducing its carbon footprint by 2030.

Investment Considerations

Strengths:

  • Innovative, non-invasive weight loss solutions.
  • Strong global presence and brand recognition.
  • Integrated approach combining medical devices and digital health.
  • Experienced leadership team and robust R&D capabilities.

Risks:

  • Dependence on a single flagship product.
  • Regulatory and compliance challenges.
  • Competitive pressures from established players.
  • Potential supply chain disruptions.

Conclusion

Allurion Technologies, Inc. is a trailblazer in the weight loss and digital health sectors. With its innovative products, global reach, and commitment to improving patient outcomes, the company is well-positioned for future growth. However, investors should carefully consider the associated risks and market dynamics before making investment decisions. As obesity rates continue to rise globally, Allurion’s solutions are likely to play a critical role in addressing this pressing health issue.